Visualizing cancer and immune cell function with metabolic positron emission tomography

Current Opinion in Genetics and Development

Volumn 20, Issue 1, 2010, Pages 100-105

  Laing, Rachel E ^a   Nair Gill, Evan ^a   Witte, Owen N ^a,b   Radu, Caius G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 DEOXY 2 FLUOROARABINOFURANOSYL)CYTOSINE; 3' FLUOROTHYMIDINE F 18; 5 AZA 2' DEOXYCYTIDINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTARABINE; CYTIDINE DERIVATIVE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENDRITIC CELL VACCINE; DEOXYCYTIDINE KINASE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IMATINIB; IMMUNOSUPPRESSIVE AGENT; NUCLEOSIDE; THYMIDINE; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL METABOLISM; CELLULAR IMMUNITY; GASTROINTESTINAL STROMAL TUMOR; GLYCOLYSIS; HUMAN; IMAGING SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 75849151738     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2009.10.008     Document Type: Review

References (58)

1. Mantovani A., Allavena P., Sica A., and Balkwill F. Cancer-related inflammation. Nature 454 (2008) 436-444. This is a comprehensive review of the complex interactions between tumors and diverse cell types of the immune system.
2. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
3. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5 (2005) 263-274
4. Frey A.B., and Monu N. Signaling defects in anti-tumor T cells. Immunol Rev 222 (2008) 192-205
5. de Visser K.E., Eichten A., and Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6 (2006) 24-37
6. Palucka A.K., Ueno H., Fay J.W., and Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 220 (2007) 129-150
7. Peggs K.S., Segal N.H., and Allison J.P. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12 (2007) 192-199
8. Paulos C.M., Suhoski M.M., Plesa G., Jiang T., Basu S., Golovina T.N., Jiang S., Aqui N.A., Powell Jr. D.J., Levine B.L., et al. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res 42 (2008) 182-196
9. Rosenberg S.A., and Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21 (2009) 233-240
10. Margolis D.J., Hoffman J.M., Herfkens R.J., Jeffrey R.B., Quon A., and Gambhir S.S. Molecular imaging techniques in body imaging. Radiology 245 (2007) 333-356
11. Phelps M.E. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 41 (2000) 661-681
12. Nair-Gill E.D., Shu C.J., Radu C.G., and Witte O.N. Non-invasive imaging of adaptive immunity using positron emission tomography. Immunol Rev 221 (2008) 214-228
13. Kang J.H., and Chung J.K. Molecular-genetic imaging based on reporter gene expression. J Nucl Med 49 Suppl 2 (2008) 164S-179S
14. Warburg O. On respiratory impairment in cancer cells. Science 124 (1956) 269-270
15. Vander Heiden M.G., Cantley L.C., and Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009) 1029-1033
16. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., and Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452 (2008) 230-233
17. Christofk H.R., Vander Heiden M.G., Wu N., Asara J.M., and Cantley L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452 (2008) 181-186
18. Shaw R.J. Glucose metabolism and cancer. Curr Opin Cell Biol 18 (2006) 598-608
19. Kim J.W., Tchernyshyov I., Semenza G.L., and Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3 (2006) 177-185
20. Deberardinis R.J., Sayed N., Ditsworth D., and Thompson C.B. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 18 (2008) 54-61. This review covers the important concepts that link oncogenic transformation to programmed changes in cellular metabolic pathways necessary for tumor progression.
21. Czernin J., and Phelps M.E. Positron emission tomography scanning: current and future applications. Annu Rev Med 53 (2002) 89-112
22. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45 (2004) 17-21
23. Goerres G.W., Stupp R., Barghouth G., Hany T.F., Pestalozzi B., Dizendorf E., Schnyder P., Luthi F., von Schulthess G.K., and Leyvraz S. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 32 (2005) 153-162
24. Stumpe K.D., Urbinelli M., Steinert H.C., Glanzmann C., Buck A., and von Schulthess G.K. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 25 (1998) 721-728
25. 18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med 113 (2008) 578-590
26. Damian D.L., Fulham M.J., Thompson E., and Thompson J.F. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 6 (1996) 325-329
27. Wagner J.D., Schauwecker D., Hutchins G., and Coleman III J.J. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 64 (1997) 181-189
28. 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med 49 (2008) 1038-1046
29. Evilevitch V., Weber W.A., Tap W.D., Allen-Auerbach M., Chow K., Nelson S.D., Eilber F.R., Eckardt J.J., Elashoff R.M., Phelps M.E., et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14 (2008) 715-720
30. Bury T., Dowlati A., Paulus P., Hustinx R., Radermecker M., and Rigo P. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 23 (1996) 204-206
31. 18F-FDG. J Nucl Med 44 (2003) 1426-1431
32. 18F-FDG PET. J Nucl Med 46 (2005) 1144-1150
33. Benz M.R., Czernin J., Allen-Auerbach M.S., Tap W.D., Dry S.M., Elashoff D., Chow K., Evilevitch V., Eckardt J.J., Phelps M.E., et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15 (2009) 2856-2863
34. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., Haase V.H., Jaenisch R., Corr M., Nizet V., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112 (2003) 645-657
35. Jones R.G., and Thompson C.B. Revving the engine: signal transduction fuels T cell activation. Immunity 27 (2007) 173-178
36. 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med 50 (2009) 920-926
37. Radu C.G., Shu C.J., Shelly S.M., Phelps M.E., and Witte O.N. Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 104 (2007) 1937-1942
38. 18F]fluoro-d-glucose and positron emission tomography. Gastroenterology 135 (2008) 744-755
39. 18F]FDG-PET from an animal model to clinical practice. It highlights the advantages of functional whole-body imaging in diagnosis and prediction of therapeutic efficacy compared to analysis of biopsy samples.
40. Elzinga E.H., van der Laken C.J., Comans E.F., Lammertsma A.A., Dijkmans B.A., and Voskuyl A.E. 2-Deoxy-2-[F-18]fluoro-d-glucose joint uptake on positron emission tomography images: rheumatoid arthritis versus osteoarthritis. Mol Imaging Biol 9 (2007) 357-360
41. Rudd J.H., Hyafil F., and Fayad Z.A. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 29 (2009) 1009-1016
42. Basu S., Chryssikos T., Moghadam-Kia S., Zhuang H., Torigian D.A., and Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 39 (2009) 36-51
43. Juweid M.E., and Cheson B.D. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354 (2006) 496-507
44. Tumeh P.C., Radu C.G., and Ribas A. PET imaging of cancer immunotherapy. J Nucl Med 49 (2008) 865-868
45. Mamede M., Saga T., Ishimori T., Nakamoto Y., Sato N., Higashi T., Mukai T., Kobayashi H., and Konishi J. Differential uptake of (18)F-fluorodeoxyglucose by experimental tumors xenografted into immunocompetent and immunodeficient mice and the effect of immunomodification. Neoplasia 5 (2003) 179-183
46. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., Obradovich J.E., Muzik O., and Mangner T.J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
47. Bading J.R., and Shields A.F. Imaging of cell proliferation: status and prospects. J Nucl Med 49 Suppl 2 (2008) 64S-80S
48. Vesselle H., Grierson J., Muzi M., Pugsley J.M., Schmidt R.A., Rabinowitz P., Peterson L.M., Vallieres E., and Wood D.E. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8 (2002) 3315-3323
49. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31 (2004) 1659-1672
50. Mankoff D.A., Shields A.F., and Krohn K.A. PET imaging of cellular proliferation. Radiol Clin North Am 43 (2005) 153-167
51. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 45 (2004) 695-700
52. 18F-fluorodeoxythymidine. J Nucl Med 49 (2008) 1756-1762
53. Arner E.S., and Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 67 (1995) 155-186
54. Eriksson S., Munch-Petersen B., Kierdaszuk B., and Arner E. Expression and substrate specificities of human thymidine kinase 1, thymidine kinase 2 and deoxycytidine kinase. Adv Exp Med Biol 309B (1991) 239-243
55. Jordheim L.P., and Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta 1776 (2007) 138-159
56. 18F]-FLT. This is a unique study showing the de novo development of a metabolic PET probe with enhanced immune imaging characteristics.
57. Faderl S., Gandhi V., Keating M.J., Jeha S., Plunkett W., and Kantarjian H.M. The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer 103 (2005) 1985-1995
58. 18F]FAC, the authors demonstrate the ability to stratify tumors based on deoxycytidine salvage activity into groups that will or will not respond to therapy with nucleoside-based chemotherapy. This study demonstrates that analysis of metabolic pathways distinct from glycolysis can provide important information about the function of cancer cells and predict their response to specific treatments.